NCT06828341View on ClinicalTrials.gov

A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

July 6, 2024

Study Completion Date

June 30, 2026

Conditions
Gliomas
Interventions
BIOLOGICAL

CAR-T

allogeneic CAR-T targeting CD70 that cultured from heathy adults.

Trial Locations (1)

210002

RECRUITING

Nanjing Jinling Hospital, China

All Listed Sponsors
collaborator

Nanjing Kanghe Cell Gene Engineering Research Institute Co., Ltd.

UNKNOWN

lead

JIANG LONGWEI

OTHER